The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
Quarterly Department
Quarterly Article
August 2025 David H. Jernigan,
Alcohol is a causal factor in more than 200 disease and injury conditions in the human body. The Centers for Disease Control and Prevention (CDC) define excessive drinking as binge drinking (4 or more drinks for women, 5 or more for men on one occasion in the past month), heavy drinking (8 or more drinks for women, 15 or more for men in a week), and any drinking during pregnancy or by persons younger than age 21 years. More
August 2025 Philip M. Alberti,
For more than 2 years, I have started my speaking engagements with a simple message: “Health equity benefits all communities.” Although the message may be straightforward, health equity–focused scientists and advocates like me have done an inadequate and ineffective job making that point clear and believable through stories, data, and messaging. More
August 2025 Rick Mayes, Micah Johnson,
From 2004 to 2024, Medicare Advantage (MA) went from being a “policy disappointment,” covering 12% of all Medicare beneficiaries, to predominance, covering more than one-half (52%), with more growth predicted in the future. Drawing on an extensive review and synthesis of the literature, Medicare Payment Advisory Commission (MedPAC) reports, congressional committee hearings, and Centers for Medicare and Medicaid Services (CMS) data, this paper analyzes the evolution of Medicare and managed care in three parts More
July 2025 BRANDON D. L. MARSHALL, Kristen Pendergrass, Sara Whaley,
The US overdose crisis is one of the most severe and devastating public health problems of the 21st century. Since 1999, more than one million Americans have lost their lives to accidental drug overdose. More
July 2025 Corey Davis, Amy Lieberman, Czarina Behrends,
The United States continues to experience a nearly unprecedented level of drug-related health harms, with over 105,000 Americans dying of overdose in 2023 alone. Although overall overdose deaths declined slightly from 2022 to 2023, rates for Black people continued to rise. Stimulants such as cocaine and methamphetamine are increasingly involved in overdose deaths, and xylazine and other contaminants continue to be prevalent in the illicit drug supply. More
July 2025 Hannah L.F. Cooper, Anna L. Mullany, Snigdha Peddireddy, Simone Wien, Melvin "Doug" Livingston, Whitney S. Rice, Anne L. Dunlop, Michael R. Kramer, Madison Haiman, Lasha S. Clarke, Natalie D. Hernandez-Green, Angélica Meinhofer,
See all articles in the special issue, Mental Health and Substance Use Challenges Facing the United States: What Can State Policymakers… More
July 2025 Gabriela Plasencia, Kamaria Kaalund, Olurotimi Kukoyi, Viviana Martinez-Bianchi, Andrea Thoumi,
Populations that identify as Latino/a/e/x or Hispanic (herein referred to as Latine) in the United States continue to face disproportion-ate health… More
July 2025 Noa Krawczyk, Hillary Samples,
The United States is facing an ongoing mental health and substance use crisis. In 2023, 58.7 million US adults had a past-year mental illness, 46.3 million had a substance use disorder (SUD), and 20.4 million had both. More
June 2025 Hannah Rahim, Aaron S. Kesselheim,
Prescription drug prices in the United States are substantially higher than in other high-income countries, with US prices reported to be an average of 2.78 times those of other countries in the Organisation for Economic Co-operation and Development.1 In response to these high prices, along with an opaque supply chain that can lead to substantial discrepancies in prices across different payors, states have passed drug price transparency laws that require manufacturers to disclose information on drug prices. More
June 2025 MATTHEW S. McCOY, MARTHA E. GAINES, STEVEN JOFFE, Genevieve Pham-Kanter, EMILY A. LARGENT, Bernard Lo, HOLLY FERNANDEZ LYNCH, ALLISON M. WHELAN, Michelle M. Mello,
Leaders at many of the country’s top academic medical centers earned—in addition to their institutional salaries—hundreds of thousands of dollars a year as directors of pharmaceutical and device companies. Critics have urged academic institutions to rethink conflict of interest policies governing leaders’ outside activities, which are understood to pose not only individual conflicts for leaders themselves but also institutional conflicts for their academic employers. More